Sonnet biotherapeutics announces first patient dosed in phase 1 clinical trial of son-1010 for advanced solid tumors

Princeton, nj / accesswire / april 13, 2022 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has been initiated in a phase 1 clinical trial of son-1010 (il12-fhab) in adult patients with advanced solid tumors. son-1010 is a proprietary version of human interleukin 12 (il-12), configured using sonnet's fully human albumin binding (fhab™) platform.
SONN Ratings Summary
SONN Quant Ranking